Comparative clinical utility of once-weekly subcutaneous abatacept in the management of rheumatoid arthritis

@inproceedings{Rakieh2014ComparativeCU,
  title={Comparative clinical utility of once-weekly subcutaneous abatacept in the management of rheumatoid arthritis},
  author={Chadi Rakieh and Philip G Conaghan},
  booktitle={Therapeutics and clinical risk management},
  year={2014}
}
Biologic therapies in rheumatoid arthritis are now part of standard practice for disease that proves difficult to control with conventional disease-modifying anti-rheumatic drugs. While anti-tumor necrosis factor therapies have been commonly used, other targeted biologic therapies with different mechanisms of action are becoming increasingly available. Abatacept is a recombinant fusion protein that inhibits the T-cell costimulatory molecules required for T-cell activation. Intravenous abatacept… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 3 times over the past 90 days. VIEW TWEETS
1 Citations
35 References
Similar Papers

References

Publications referenced by this paper.
Showing 1-10 of 35 references

Safety profile of subcutaneous abatacept focusing on clinically relevant events in patients with rheumatoid arthritis (RA) and up to 4.5 years of exposure

  • R Alten, J Kaine, E Keystone
  • Arthritis Rheum. 2011;63:S150
  • 2011
Highly Influential
5 Excerpts

update

  • JL Nam, S Ramiro, C Gaujoux-Viala
  • Ann Rheum Dis
  • 2014

Similar Papers

Loading similar papers…